<DOC>
	<DOCNO>NCT01803022</DOCNO>
	<brief_summary>The study purpose document prescription use Low Molecular Weight Heparin usual medical practice patient cancer establish Venous Thromboembolism . This study also aim gather epidemiological data Low Molecular Weight Heparin therapy Venous Thromboembolism patient cancer .</brief_summary>
	<brief_title>Prescription Utilization Low Molecular Weight Heparin Usual Medical Practice Curative Treatment Venous Thromboembolism Patients With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Subjects must provide informed consent Men woman age 18 year Ongoing cancer disease recent diagnosis veinous thromboembolism treatment Low Molecular Weight Heparin entry study Contraindication use Low Molecular Weight Heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Cancer</keyword>
	<keyword>Low Molecular Weight Heparin</keyword>
</DOC>